View More Recent Stories
-
Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) Receives FDA’s Regenerative Medicine Advanced Therapy Designation for BBP-812
-
BridgeBio Pharma (BBIO) Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy
-
Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY)
-
Mizuho Reiterates Outperform Rating on BridgeBio Pharma (BBIO)
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
BridgeBio Pharma (BBIO) Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
-
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises
-
BridgeBio Pharma Inc. (BBIO) Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with M
-
BridgeBio Pharma Inc. (BBIO) Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
-
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
-
BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 41c
-
BridgeBio Pharma Inc. (BBIO) Appoints Thomas Trimarchi as COO
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect the topline nominal win for HELIOS-B will send BBIO shares downward'
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
Evercore ISI on HELIOS-B Read-Through to BridgeBio Pharma (BBIO)
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
-
BridgeBio Pharma Inc. (BBIO) Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418
-
TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)
